These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Fattore L; Cossu G; Martellotta CM; Fratta W Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718 [TBL] [Abstract][Full Text] [Related]
3. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Vlachou S; Nomikos GG; Panagis G Behav Brain Res; 2003 May; 141(2):215-22. PubMed ID: 12742258 [TBL] [Abstract][Full Text] [Related]
4. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Spano MS; Fattore L; Cossu G; Deiana S; Fadda P; Fratta W Br J Pharmacol; 2004 Oct; 143(3):343-50. PubMed ID: 15339858 [TBL] [Abstract][Full Text] [Related]
5. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Pan X; Ikeda SR; Lewis DL Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635 [TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Darmani NA Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062 [TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Gamaleddin I; Wertheim C; Zhu AZ; Coen KM; Vemuri K; Makryannis A; Goldberg SR; Le Foll B Addict Biol; 2012 Jan; 17(1):47-61. PubMed ID: 21521420 [TBL] [Abstract][Full Text] [Related]
8. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305 [TBL] [Abstract][Full Text] [Related]
9. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Chaperon F; Soubrié P; Puech AJ; Thiébot MH Psychopharmacology (Berl); 1998 Feb; 135(4):324-32. PubMed ID: 9539255 [TBL] [Abstract][Full Text] [Related]
11. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. Gifford AN; Ashby CR J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207 [TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. McMahon LR Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389 [TBL] [Abstract][Full Text] [Related]
13. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Richter A; Löscher W Eur J Pharmacol; 2002 Nov; 454(2-3):145-51. PubMed ID: 12421641 [TBL] [Abstract][Full Text] [Related]
14. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. Pozzi O; Misiano P; Clark GD; Visentin L Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703 [TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Kathmann M; Weber B; Schlicker E Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):50-6. PubMed ID: 11191836 [TBL] [Abstract][Full Text] [Related]
16. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Maneuf YP; Crossman AR; Brotchie JM Exp Neurol; 1997 Nov; 148(1):265-70. PubMed ID: 9398468 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190 [TBL] [Abstract][Full Text] [Related]
19. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release. Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637 [TBL] [Abstract][Full Text] [Related]
20. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Martellotta MC; Cossu G; Fattore L; Gessa GL; Fratta W Neuroscience; 1998 Jul; 85(2):327-30. PubMed ID: 9622233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]